An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination With Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination With Cyclophosphamide, Followed by CMF, in the Adjuvant Treatment of Node-Positive Breast Cancer Patients.

Trial Profile

An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination With Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination With Cyclophosphamide, Followed by CMF, in the Adjuvant Treatment of Node-Positive Breast Cancer Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Cyclophosphamide; Doxorubicin; Fluorouracil; Methotrexate
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
    • 09 Nov 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
    • 09 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top